CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 70 enrolled
Drug / intervention
bupivicaine +3 moredrug
Likely dose
bupivicaine 2.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00915473
NCT00915473Phase 4Completed
CompareCT.gov

Greater Occipital Nerve Block for Migraine Prophylaxis

Mayo Clinic·interventional·Posted Jun 8, 2009·Updated Mar 20, 2014

In Brief

A Phase 4 clinical trial evaluating bupivicaine, normal saline, and 2 other interventions for Migraine Headache. Completed, enrolled 70 participants across 1 site.

Detailed Summary

Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS)

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 8, 2009
Enrollment StartJun 1, 2009
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 17.1 years ago

Interventions

bupivicainedrug

2.5 mL 0.5% bupivicaine

normal salinedrug

2.75 mL normal saline

methylprednisolonedrug

0.5 mL 20 mg methylprednisolone

lidocainedrug

0.25 mL 1% lidocaine